Randomised, double-blind, placebo-controlled study of pivagabine in neurasthenia.
Arzneimittelforschung
; 47(11A): 1329-31, 1997 Nov.
Article
in En
| MEDLINE
| ID: mdl-9450159
ABSTRACT
One hundred and eighteen patients with neurasthenia, as defined by ICD 10 (International Classification of Diseases), participated in a randomised, double-blind, placebo-controlled trial of pivagabine (4-[(2,2-dimethyl-1-oxopropyl)amino]butanoic acid, CAS 69542-93-4, Tonerg). Pivagabine 1800 mg/d was administered orally for four weeks. At the end of the trial, active medication was significantly superior to placebo on the Clinical Global Impression (CGI) improvement of illness scale. In addition, pivagabine treatment reduced the physical and mental fatigability of patients, and increased their sense of well-being.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Psychotropic Drugs
/
Gamma-Aminobutyric Acid
/
Neurasthenia
Type of study:
Clinical_trials
Limits:
Adolescent
/
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Arzneimittelforschung
Year:
1997
Document type:
Article
Affiliation country:
Italy